- Home
- NUVB vs FMBH Comparison
NUVB vs FMBH Comparison
Compare NUVB & FMBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- FMBH
- Stock Information
- Founded
- NUVB 2018
- FMBH 1865
- Country
- NUVB United States
- FMBH United States
- Employees
- NUVB N/A
- FMBH N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- FMBH Major Banks
- Sector
- NUVB Health Care
- FMBH Finance
- Exchange
- NUVB Nasdaq
- FMBH Nasdaq
- Market Cap
- NUVB 1.1B
- FMBH 974.1M
- IPO Year
- NUVB N/A
- FMBH N/A
- Fundamental
- Price
- NUVB $5.04
- FMBH $36.70
- Analyst Decision
- NUVB Strong Buy
- FMBH Hold
- Analyst Count
- NUVB 7
- FMBH 5
- Target Price
- NUVB $8.43
- FMBH $43.40
- AVG Volume (30 Days)
- NUVB 8.2M
- FMBH 54.2K
- Earning Date
- NUVB 11-03-2025
- FMBH 10-27-2025
- Dividend Yield
- NUVB N/A
- FMBH 2.73%
- EPS Growth
- NUVB N/A
- FMBH 13.11
- EPS
- NUVB N/A
- FMBH 3.52
- Revenue
- NUVB $14,355,000.00
- FMBH $328,480,000.00
- Revenue This Year
- NUVB $291.13
- FMBH N/A
- Revenue Next Year
- NUVB $332.00
- FMBH $4.16
- P/E Ratio
- NUVB N/A
- FMBH $10.42
- Revenue Growth
- NUVB 900.35
- FMBH 7.81
- 52 Week Low
- NUVB $1.54
- FMBH $27.58
- 52 Week High
- NUVB $5.12
- FMBH $43.86
- Technical
- Relative Strength Index (RSI)
- NUVB 76.90
- FMBH 46.47
- Support Level
- NUVB $3.36
- FMBH $36.32
- Resistance Level
- NUVB $3.84
- FMBH $37.27
- Average True Range (ATR)
- NUVB 0.29
- FMBH 1.04
- MACD
- NUVB 0.11
- FMBH 0.16
- Stochastic Oscillator
- NUVB 95.45
- FMBH 68.54
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
About FMBH First Mid Bancshares Inc.
First Mid Bancshares Inc is a United States based financial holding company. Through its wholly-owned subsidiary, First Mid Bank, it is engaged in the business of banking. The Company offers trust, farm services, investment services, and retirement planning through its wholly owned subsidiary, it also provides data processing services to affiliates and insurance products and services to customers through its subsidiary. The company's operations cover community banking, wealth management and insurance services. Key revenue is derived from the provision of community banking services.